Addison Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Addison Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$146K	Buy	328 +2	+0.6%	+$933	0.03%	263
2025 Q4	$148K	Sell	326 -6	-2%	-$2.59K	0.03%	264
2025 Q3	$130K	Sell	332 -11	-3%	-$4.6K	0.03%	280
2025 Q2	$153K	Sell	343 -16	-4%	-$7.37K	0.04%	251
2025 Q1	$174K	Buy	359 +16	+5%	+$7.46K	0.05%	226
2024 Q4	$138K	Buy	343 +11	+3%	+$5.1K	0.04%	259
2024 Q3	$154K	Buy	332 +3	+0.9%	+$1.44K	0.04%	252
2024 Q2	$154K	Buy	329 +17	+5%	+$7.38K	0.05%	236
2024 Q1	$130K	Hold	312	–	–	0.04%	257
2023 Q4	$127K	Hold	312	–	–	0.05%	248
2023 Q3	$108K	Buy	312 +12	+4%	+$4.2K	0.05%	241
2023 Q2	$106K	Hold	300	–	–	0.05%	237
2023 Q1	$94.5K	Sell	300 -17	-5%	-$5.1K	0.05%	233
2022 Q4	$91.5K	Buy	317 +2	+0.6%	+$610	0.05%	224
2022 Q3	$91K	Hold	315	–	–	0.06%	199
2022 Q2	$89K	Buy	315 +2	+0.6%	+$535	0.05%	201
2022 Q1	$82K	Hold	313	–	–	0.04%	228
2021 Q4	$69K	Buy	+313	New	+$60.9K	0.04%	216

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Addison Advisors's VRTX Position: Q1 2026 in Review

Addison Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.61% in Q1 2026, buying an estimated $933 and bringing the position to 328 shares worth $146K. The position accounts for 0.03% of the portfolio, ranked #263.

Addison Advisors first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $174K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Addison Advisors held 328 shares of Vertex Pharmaceuticals worth $146K as of Q1 2026.
Addison Advisors bought 2 Vertex Pharmaceuticals shares in Q1 2026, an estimated $933.
Vertex Pharmaceuticals made up 0.03% of Addison Advisors's portfolio in Q1 2026, its #263 holding.
Addison Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Addison Advisors's Vertex Pharmaceuticals position peaked at $174K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Addison Advisors's 13F filing for Q1 2026, filed 8 May 2026.